Stay updated on Pembrolizumab in Lymphopenic Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Lymphopenic Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Lymphopenic Breast Cancer Clinical Trial page
- Check4 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant piece of information regarding the modernization of ClinicalTrials.gov data ingest in July 2025 has been deleted.SummaryDifference1.0%
- Check11 days agoNo Change Detected
- Check19 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.8%
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check40 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check69 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check83 days agoChange DetectedThe page has undergone significant updates, including the addition of the term 'Metastatic Breast Cancer' and the EudraCT number for a clinical trial, while extensive details about the trial's methodology and inclusion criteria have been removed.SummaryDifference48%
Stay in the know with updates to Pembrolizumab in Lymphopenic Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Lymphopenic Breast Cancer Clinical Trial page.